Trials / Conditions / Stage IV Colon Cancer AJCC v8

Stage IV Colon Cancer AJCC v8

17 registered clinical trials studyying Stage IV Colon Cancer AJCC v8 — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Family Communications After Genetic Testing NCT07143487	Alliance for Clinical Trials in Oncology	N/A
Withdrawn	Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Met NCT06575725	City of Hope Medical Center	Phase 2
Withdrawn	Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cance NCT05356897	Academic and Community Cancer Research United	Phase 2
Active Not Recruiting	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Micro NCT05627635	City of Hope Medical Center	Phase 1 / Phase 2
Active Not Recruiting	Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorecta NCT05308446	National Cancer Institute (NCI)	Phase 2
Recruiting	Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery NCT05296681	Howard S. Hochster, MD	Phase 2
Recruiting	Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events NCT05038254	M.D. Anderson Cancer Center	N/A
Completed	18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases NCT04752267	University of Southern California	EARLY_Phase 1
Active Not Recruiting	LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastat NCT04616183	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the S NCT04599140	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metast NCT04362839	City of Hope Medical Center	Phase 1
Active Not Recruiting	Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type C NCT03992456	Academic and Community Cancer Research United	Phase 2
Terminated	Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Tr NCT03765736	Academic and Community Cancer Research United	—
Completed	TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Ca NCT04109924	Roswell Park Cancer Institute	Phase 2
Terminated	Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer NCT03592641	National Cancer Institute (NCI)	Phase 2
Completed	M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instabil NCT03436563	M.D. Anderson Cancer Center	Phase 1 / Phase 2